Safety of adenosine pharmacologic stress myocardial perfusion imaging in orthotopic cardiac transplant recipients: a single center experience of 102 transplant patients
- 147 Downloads
Denervation super-sensitivity to adenosine is well described in cardiac transplant (CT) patients particularly early after transplant. The safety and hemodynamic effects of adenosine SPECT (A-SPECT) has not been described in a large series of CT patients. Single center retrospective study of 102 CT patients undergoing A-SPECT were compared to an age-gender matched patients in a 2:1 fashion who underwent A-SPECT in the same time period. Multivariate logistic regression model were used to identify independent predictors of advanced AV block. The average time from CT to A-SPECT was 8.5 ± 4.5 years. Average age was 57 years with 80% males. In comparison to the control group, adenosine infusion was associated with a higher incidence of sinus pause (4.9% vs. 0%), 2nd (11.8% vs. 4.9%) and 3rd degree AVB (2.9% vs. 0%) in CT patients (all P < 0.05). Prior use of aspirin and baseline 1st degree AVB were significant independent predictors of adenosine induced AVB. Baseline right or left bundle branch block, beta-blockers, calcium blockers or digoxin were not associated with occurrence of AVB. Only 1.9% of A-SPECT studies were terminated due to bradyarrythmia with 1 patient requiring aminophylline. There were no significant immediate or long term adverse events in these patients. Adenosine pharmacologic stress is associated with a higher incidence of AVB and sinus pause in CT patients reflecting persistence of super sensitivity late after CT. Nevertheless these bradyarrythmias are transient without any sequelae suggesting that A-SPECT can be performed safely in CT patients.
KeywordsAdenosine Cardiac transplantation Single photon emission computed tomography Atrioventricular block Denervation supersensitivity
Research Grant Support: Astellas Global Pharma Development Inc, GE Healthcare, American Society of Echocardiography. Speakers Bureau, Honoraria: Astellas Pharma Global Development Inc, Lantheus Medical Imaging. Consultant: Lantheus Medical Imaging.
- 1.Taylor DO, Edwards LB, Boucek MM, Trulock EP, Deng MC, Keck BM, Hertz MI (2005) Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report–2005. J Heart Lung Transplant 24:945–955. doi: 10.1016/j.healun.2005.05.018 PubMedCrossRefGoogle Scholar
- 2.The International Society for Heart and Lung Transplantation. Registries—Heart/Lung RegistriesGoogle Scholar
- 7.Ciliberto GR, Ruffini L, Mangiavacchi M, Parolini M, Sara R, Massa D, De Maria R, Gronda E, Vitali E, Parodi O (2001) Resting echocardiography and quantitative dipyridamole technetium-99 m sestamibi tomography in the identification of cardiac allograft vasculopathy and the prediction of long-term prognosis after heart transplantation. Eur Heart J 22:964–971. doi: 10.1053/euhj.2000.2422 PubMedCrossRefGoogle Scholar
- 14.Alkoutami GS, Reeves WC, Movahed A (1999) The safety of adenosine pharmacologic stress testing in patients with first-degree atrioventricular block in the presence and absence of atrioventricular blocking medications. J Nucl Cardiol 6:495–497. doi: 10.1016/S1071-3581(99)90021-1 PubMedCrossRefGoogle Scholar